Sign In to Request a Protocol
Sign In to Request a Protocol

CJC-1295 NO DAC (5 mg Vial)

  • Table of Contents

CJC-1295 NO DAC Dosage Chart

CJC-1295 NO DAC is commonly studied in educational and research protocols at doses ranging from 100–300 mcg daily by subcutaneous injection.
  • Reconstitution: Add 3.0 mL of bacteriostatic water to a 5 mg vial to achieve an approximate concentration of 1.67 mg/mL.
  • Typical Daily Dose: 100–300 mcg once daily, with optional gradual titration depending on the planned protocol.
  • Measurement Guide: At a concentration of 1.67 mg/mL, 1 unit (0.01 mL) on a U-100 insulin syringe delivers approximately 16.7 mcg.
  • Storage: Store lyophilized vials refrigerated at 2–8 °C (35.6–46.4 °F). After reconstitution, keep refrigerated and use within 1–2 weeks. For longer-term storage, keep lyophilized vials frozen at ≤ −20 °C (≤ −4 °F).
CJC-1295 NO DAC (also known as Modified GRF 1–29 or Mod GRF) is a synthetic 29-amino-acid growth hormone-releasing hormone (GHRH) analog. It is studied for its ability to stimulate the body’s natural, pulsatile release of growth hormone from the pituitary gland. Unlike direct growth hormone administration, CJC-1295 NO DAC is designed to support the body’s normal hormonal signaling pathways. Research suggests it may help promote healthy growth hormone (GH) and IGF-1 activity while maintaining the body’s natural hormone release patterns. Preclinical and limited clinical research has explored its potential to support body composition, recovery, sleep quality, lean muscle maintenance, and metabolic function. This protocol outlines a once-daily subcutaneous administration approach using a practical dilution designed to provide clear and consistent insulin syringe measurements.
  • Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

PhaseDaily Dose (mg)Units (per injection) (mL)Volume (mL)
Weeks 1–20.6 mg36 units0.36 mL
Weeks 3–41.2 mg72 units0.72 mL
Weeks 5–62.4 mg144 units1.44 mL
Weeks 7–16 (Maintenance)4.5 mg270 units2.70 mL

Note: Doses above 1.0 mL (100 units) require a 3 mL syringe with an appropriate subcutaneous needle (e.g., 25–27G, ½–⅝ inch) rather than a standard U‑100 insulin syringe. For lower starting doses (≤72 units), a U‑100 insulin syringe provides excellent accuracy.

Reconstitution Steps

  • 1. Draw 3.0 mL of bacteriostatic water using a sterile syringe.
  • 2. Inject the water slowly down the inside wall of the vial to help minimize foaming.
  • 3. Gently swirl or roll the vial until the powder has completely dissolved. Do not shake the vial.
  • 4. Label the vial with the reconstitution date and store it refrigerated at 2–8 °C (35.6–46.4 °F), protected from direct light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

  • Supplies Needed

Plan based on an 8–12 week daily protocol with gradual titration.

  • Peptide Vials (CJC-1295 NO DAC, 5 mg each)
  • 8 weeks: Approximately 2 vials
  • 12 weeks: Approximately 3 vials
  • 16 weeks: Approximately 4 vials
  • Insulin Syringes (U-100)
  • Per week: 7 syringes (1 per day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles) Use 3.0 mL per vial for reconstitution.
  • 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
  • 12 weeks (3 vials): 9 mL → 1 × 10 mL bottle
  • 16 weeks (4 vials): 12 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each week.
  • Per week: 14 swabs (2 per day)
  • 8 weeks: 112 swabs → Recommended: 2 × 100-count boxes
  • 12 weeks: 168 swabs → Recommended: 2 × 100-count boxes
  • 16 weeks: 224 swabs → Recommended: 3 × 100-count boxes
  • Protocol Overview

A concise overview of the once-daily CJC-1295 NO DAC protocol.

  • Goal: Support the body's natural pulsatile growth hormone (GH) release and healthy IGF-1 activity to promote body composition, recovery, and overall metabolic function.
  • Schedule: One subcutaneous injection daily for 8–12 weeks, with the option to continue for up to 16 weeks if desired.
  • Dose Range: 100–300 mcg daily with gradual titration based on the planned protocol.
  • Reconstitution: Reconstitute each 5 mg vial with 3.0 mL of bacteriostatic water to achieve an approximate concentration of 1.67 mg/mL for accurate dosing.
  • Storage: Store lyophilized vials refrigerated or frozen until use. After reconstitution, refrigerate and avoid repeated freeze–thaw cycles.
  • Dosing Protocol

A suggested daily titration approach for the planned protocol.

  • Starting Dose: 100–150 mcg once daily.
  • Titration: Increase the dose by approximately 50 mcg every 1–2 weeks, if following a gradual titration plan.
  • Target Dose: 200–300 mcg once daily by Weeks 5–12.
  • Frequency: One subcutaneous injection per day, preferably administered at bedtime.
  • Cycle Length: Standard protocol is 8–12 weeks, with an optional extension to 16 weeks.
  • Timing: Bedtime administration is preferred to align with the body's natural nighttime growth hormone release. Rotate injection sites regularly to support consistent injection practices.
  • Storage Instructions

Proper storage helps maintain peptide stability and quality.

  • Lyophilized Vials: Store at 2–8 °C (35.6–46.4 °F). For extended storage, keep frozen at ≤ −20 °C (≤ −4 °F). Minimize exposure to moisture.
  • Reconstituted Solution: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within 1–2 weeks. Avoid repeated freeze–thaw cycles.
  • Before Opening: Allow the vial to reach room temperature before opening to help minimize condensation inside the vial.
  • Important Notes
Practical considerations for consistency and tolerability.
  • Use new sterile syringes for each injection; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) weekly to reduce local irritation.
  • Gradual dose escalation minimizes gastrointestinal side effects such as nausea.
  • Document weekly dose, injection site, and any adverse effects to maintain consistency.
  • For maintenance doses requiring >1.0 mL, ensure you have appropriately sized syringes (3 mL).
  • How This Works
CJC-1295 NO DAC (Modified GRF 1–29) is a synthetic growth hormone-releasing hormone (GHRH) analog designed with amino acid modifications that improve its stability and resistance to enzymatic breakdown. It works by binding to GHRH receptors on pituitary cells, helping stimulate the body’s natural, pulsatile release of growth hormone (GH). Unlike direct growth hormone administration, CJC-1295 NO DAC is intended to support the body’s normal hormonal signaling and feedback mechanisms, promoting a more natural pattern of GH release. Because of its relatively short duration of action, CJC-1295 NO DAC is studied for its ability to produce discrete GH pulses that more closely resemble the body’s normal physiological secretion pattern. Note: Current evidence is based primarily on preclinical research and limited human studies. Additional clinical research is needed to further evaluate the safety and effectiveness of CJC-1295 NO DAC.
  • Potential Benefits & Side Effects

The following observations are based on preclinical research and limited clinical studies of GHRH analogs.

  • May support the body's natural growth hormone (GH) release and healthy IGF-1 activity.
  • May help support improvements in body composition, including increased lean muscle mass and reduced body fat.
  • May contribute to recovery, sleep quality, and overall energy levels.
  • Lifestyle Factors
Complementary strategies for optimal outcomes.
  • Pair with a balanced, protein‑forward diet tailored to individual energy needs.
  • Combine resistance training and aerobic activity to support metabolic health and preserve lean mass.
  • Prioritize adequate sleep (7–9 hours) and stress management for adherence and recovery.
  • Monitor hydration and electrolytes, especially if experiencing gastrointestinal side effects.
  • Injection Technique

General guidance for subcutaneous injection based on established clinical best practices.

  • Clean the vial stopper and the injection site with an alcohol swab, then allow both to dry completely before injecting.
  • Pinch a fold of skin and insert the needle into the subcutaneous tissue at a 45°–90° angle, depending on the injection site and needle length.
  • Inject slowly and steadily. Aspiration is generally not required for subcutaneous injections.
  • b>Rotate injection sites regularly (such as the abdomen, thighs, and upper arms) to help minimize local irritation and reduce the risk of tissue changes with repeated injections.
  • Recommended Source
We recommend Vitality Labs Peptides for high‑purity CJC-1295 NO DAC (5 mg).

Why Vitality Labs Peptides?

  • High-purity, third-party-tested lots with batch COAs.
  • Consistent, ISO-aligned handling and documentation.
  • Reliable fulfillment to maintain cold-chain integrity.
Contact on Telegram
  • Important Note

This content is for educational purposes only and is not medical advice.

  • References

Wikipedia

Modified GRF (1–29): structure, amino acid substitutions, and pharmacokinetics

More Info

Journal of Clinical Endocrinology & Metabolism (2006)

— Teichman et al.: Prolonged stimulation of GH and IGF‑I by CJC-1295 in healthy adults
More Info

American Journal of Physiology (2006)

— Alba et al.: Once‑daily CJC-1295 normalizes growth in GHRH knockout mice
More Info

Journal of Clinical Endocrinology & Metabolism (2006)

— Veldhuis et al.: Pulsatile GH secretion persists during continuous CJC-1295 stimulation
More Info

PMC

Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF‑1 Levels

More Info

PMC

 Effects of GHRH Analog (Tesamorelin) on Endogenous GH Pulsatility and Insulin Sensitivity

More Info

PMC

— Sermorelin: a better approach to management of adult‑onset growth hormone insufficiency
More Info

PMC

Beyond the androgen receptor: role of GHS in body composition in hypogonadal males

More Info

PMC

The Safety and Efficacy of Growth Hormone Secretagogues (Review)
More Info

PMC

GHRH Effects on Brain GABA Levels in Mild Cognitive Impairment and Healthy Aging
More Info

PubMed

Sermorelin: review of its use in diagnosis and treatment of GH deficiency

More Info

CDC

Vaccine administration: subcutaneous route (angle/site; no aspiration)

More Info

CDC (Subcut Injection PDF)

Technique diagram and site guidance for subcutaneous injections

More Info

NCBI Bookshelf

Best practices for injection (asepsis, preparation, and administration)

More Info

Subcutaneous Drug Injection Review (PMC)

— Pharmacologic considerations of the subcutaneous route
More Info

Vitality Labs Peptides

CJC-1295 NO DAC (5 mg) product page (quality and batch documentation)

More Info